Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Neuro Oncol. 2021 Aug 2;23(8):1415. doi: 10.1093/neuonc/noaa115.
No abstract available

Publication types

  • Published Erratum

Grants and funding